Avidicure launches with focus on multifunctional antibodies to treat cancer
April 25, 2025
Avidicure BV has launched with a $50 million seed financing round and a focus on developing dual agonistic, multifunctional and avidity engineered antibodies, or AVC-Boosters, to deliver targeted and potent cancer monotherapy.